Day: March 23, 2023

Itafos Reports Record Q4 and FY 2022 Results

Written by Customer Service on March 23, 2023. Posted in Earnings Releases And Operating Results.

HOUSTON, March 23, 2023 (GLOBE NEWSWIRE) — Itafos Inc. (TSX-V: IFOS) (the “Company”) reported today its Q4 and FY 2022 financial and operational highlights. The Company’s financial statements and management’s discussion and analysis and annual information form for the year ended December 31, 2022 are available under the Company’s profile at www.sedar.com and on the Company’s website at www.itafos.com. All figures are in thousands of US Dollars except as otherwise noted. CEO Commentary “We are pleased to report record safety performance and financial results for 2022. The 2022 reported revenues of $593.3 million and adjusted EBITDA of $224.8 million were supported by strong production performance at our Conda facility and improved market fundamentals for the agricultural sector.” “Over the last 24 months we have successfully executed...

Perma-Fix Reports Financial Results and Provides Business Update for 2022

Written by Customer Service on March 23, 2023. Posted in Earnings Releases And Operating Results.

Treatment Segment on growth path heading into 2023with increased waste receipts and improved backlog Services Segment secures important projects expected to begin in Q2 2023 Reports progress on key strategic initiatives ATLANTA, March 23, 2023 (GLOBE NEWSWIRE) — Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update for the fourth quarter and full year ended December 31, 2022. Mark Duff, President and CEO of the Company, commented, “While 2022 was a challenging year due to the lingering effects of the COVID-19 pandemic, which delayed projects in both the Treatment and Services Segments, we believe we are back on the growth trajectory. Within our Treatment Segment, we have experienced a steady improvement in waste receipts, particularly in the last...

Orion and Bayer expand clinical development program for darolutamide in prostate cancer

Written by Customer Service on March 23, 2023. Posted in Public Companies.

ORION CORPORATION PRESS RELEASE 23 March 2023 at 15:00 EET Orion and Bayer expand clinical development program for darolutamide in prostate cancerPhase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline Fifth major clinical trial for androgen receptor inhibitor (ARi) darolutamide, covering prostate cancer from early to metastatic stageOrion and Bayer further expand the global clinical development program for the oral androgen receptor inhibitor (ARi) darolutamide in prostate cancer. The new Phase III clinical study, ARASTEP, will investigate the efficacy of darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive...

Rail Vision Announces Fourth Quarter and Full Year 2022 Financial Results

Written by Customer Service on March 23, 2023. Posted in Earnings Releases And Operating Results.

RA’ANANA, Israel, March 23, 2023 (GLOBE NEWSWIRE) — Rail Vision Ltd. (Nasdaq: RVSN) (“Rail Vision” or the “Company”), a development stage technology company seeking to revolutionize railway safety and the data-related market, today reported financial results for the fourth quarter and fiscal year ended December 31, 2022. “Capital from our Nasdaq IPO enabled us to strengthen our foundation during fiscal 2022, positioning us to pursue multiple exciting opportunities to accelerate new customer acquisitions in 2023 and beyond,” commented Shahar Hania, CEO of Rail Vision. “Our recent successes, including the Israeli Railways deal and US-based rail services customer agreement, demonstrate that our solutions are gaining traction among potential customers. We remain confident in our ability to create value for shareholders...

Aircraft Flight Control System Market is Estimated to Hit USD 20.84 Billion by 2028 at a CAGR of 6.03% from 2022 to 2028; Surge in Demand for Commercial Aircraft due to the Substantial Growth in Air Travel to Fuel Market Growth

Written by Customer Service on March 23, 2023. Posted in Mergers And Acquisitions.

SkyQuest’s latest report is a valuable resource that provides businesses with comprehensive insights into the key growth areas and innovations in the aircraft flight control system market. The report offers a crucial analysis of the market’s trends, opportunities, challenges, and competitive landscape, enabling businesses to make data-driven decisions that can enhance their operations. Moreover, the report provides a holistic view of the market, covering various segments and general aviation and highlighting the emerging trends and opportunities in each segment. This can help businesses tailor their strategies and offerings to meet the specific needs of different customer segments, thereby improving their competitiveness, profitability, and customer satisfaction. Westford USA, March 23, 2023 (GLOBE NEWSWIRE) — The aircraft...

Trinity Biotech Announces Fourth Quarter and Fiscal Year 2022 Financial Results

Written by Customer Service on March 23, 2023. Posted in Earnings Releases And Operating Results.

DUBLIN, Ireland, March 23, 2023 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2022 and fiscal year 2022. Summary Highlights Revenue:Total revenues for fiscal year 2022 and Q4, 2022 were $74.8m and $18.0m respectively. Excluding our Covid focused PCR Viral Transport Media (“VTM”) products, full year 2022 revenues of $71.5m were 1.0% lower than in 2021 and Q4, 2022 revenues were 0.4% lower than in Q4, 2021. Our performance in 2022 was focused on our core flagship haemoglobins business, where our main diabetes product line experienced 27% overall revenue growth and over 60% higher instrument placements versus 2021. As highlighted by the 43% growth in...

CAPREIT Announces Timing of First Quarter 2023 Results & Conference Call

Written by Customer Service on March 23, 2023. Posted in Public Companies.

TORONTO, March 23, 2023 (GLOBE NEWSWIRE) — Canadian Apartment Properties Real Estate Investment Trust (“CAPREIT”) (TSX:CAR.UN) announced today it will issue its financial results for the three months ended March 31, 2023 after markets close on: Friday, May 12, 2023 A conference call to discuss the results will be hosted by the CAPREIT senior management team on: Monday, May 15, 2023 at 9:00 am ET The telephone numbers for the conference call are: Canadian Toll Free: (833) 950-0062International: +1 (929) 526-1599Access Code: 497373 The call will also be webcast live and accessible through the CAPREIT website at www.capreit.ca – click on “For Investors” and follow the link at the top of the page. A replay of the webcast will be available for 1 year after the webcast at the same link. The slide presentation to accompany management’s...

ERES REIT Announces Timing of First Quarter 2023 Results & Conference Call

Written by Customer Service on March 23, 2023. Posted in Public Companies.

TORONTO, March 23, 2023 (GLOBE NEWSWIRE) — European Residential Real Estate Investment Trust (“ERES”) (TSX:ERE.UN) announced today it will issue its financial results for the three months ended March 31, 2023 after markets close on: Wednesday, May 10, 2023 A conference call to discuss the results will be hosted by Phillip Burns, Chief Executive Officer and Jenny Chou, Chief Financial Officer on: Thursday, May 11, 2023 at 9:00 am ET The telephone numbers for the conference call are: Canadian Toll Free: (833) 950-0062 International: + 1 (929) 526-1599 Access Code: 119808 The call will also be webcast live and accessible through the ERES website at www.eresreit.com – click on “Investor Info” and follow the link at the top of the page. A replay of the webcast will be available for 1 year after the webcast at the same link. The...

Pan American Energy Retains Clarus Securities for Capital Markets Services

Written by Customer Service on March 23, 2023. Posted in Mergers And Acquisitions.

CALGARY, Alberta, March 23, 2023 (GLOBE NEWSWIRE) — Pan American Energy Corp. (the “Company” or “Pan American”) (CSE: PNRG) (OTC PINK: PAANF) (FRA: SS6) is pleased to announce that it has retained the services of Clarus Securities Inc. (“Clarus”) to act as financial advisor to the Company. The Company has entered into a services agreement (the “Agreement“) with Clarus, pursuant to which Clarus has agreed to perform the following capital markets support services, including but not limited to; introducing the Company to capital market participants and/or institutional investors that may include investment funds, mutual funds, private capital sources or other potential strategic investors; introducing the Company to industry participants as well as strategic investors as potential joint-venture partners, as requested;...

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results

Written by Customer Service on March 23, 2023. Posted in Earnings Releases And Operating Results.

On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and Report Topline Results by the Fourth Quarter of 2024 Projected Cash Runway into First Half of 2025 NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the fourth quarter and full year ended December 31, 2022. “Meaningful progress has been made this year as we streamlined our product candidate portfolio to focus on our most promising asset. We believe Landos is uniquely positioned to transform the treatment paradigm for patients with ulcerative colitis with our novel, oral, once-daily treatment NX-13,”...

Day: March 23, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice